HuGE Literature Finder
Records
1
-
6
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. Pharmacogenetics and genomics 2021 Jul 31 (5): 116-123. Hertz Daniel L, Douglas Julie A, Kidwell Kelley M, Gersch Christina L, Desta Zeruesenay, Storniolo Ana-Maria, Stearns Vered, Skaar Todd C, Hayes Daniel F, Henry N Lynn, Rae James |
Effect of Genetic Polymorphisms and Long-Term Tobacco Exposure on the Risk of Breast Cancer. International journal of molecular sciences 2016 Oct 17 (10): . Verde Zoraida, Santiago Catalina, Chicharro Luis Miguel, Reinoso-Barbero Luis, Tejerina Alejandro, Bandrés Fernando, Gómez-Gallego Fél |
Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers. Current drug metabolism 2015 16 (10): 850-63. He Xin, Feng Sh |
The pharmacokinetics of letrozole: association with key body mass metrics. International journal of clinical pharmacology and therapeutics 2012 Aug 50 (8): 557-65. Jin Seok-Joon, Jung Jin Ah, Cho Sang-Heon, Kim Un-Jib, Choe Sangmin, Ghim Jong-Lyul, Noh Yook-Hwan, Park Hyun-Jung, Kim Jung-Chul, Jung Jin-A, Lim Hyeong-Seok, Bae Kyun-Se |
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clinical pharmacology and therapeutics 2011 Nov 90 (5): 693-700. Desta Z, Kreutz Y, Nguyen A T, Li L, Skaar T, Kamdem L K, Henry N L, Hayes D F, Storniolo A M, Stearns V, Hoffmann E, Tyndale R F, Flockhart D |
Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women. European journal of clinical pharmacology 2011 Oct 67 (10): 1017-25. Tanii Hiromi, Shitara Yoshihisa, Horie Toshiha |
- Page last reviewed:Oct 1, 2021
- Page last updated:May 26, 2022
- Content source: